Source comparison
Best Thymosin Alpha-1 Dosage Infection Defense 2026: Protocol Comparison
Acute Viral Defense 6.4mg initial, then 3.2mg maintenance Day 1, then 2× weekly 4–8 weeks Rapid dendritic cell maturation and CD8+ T-cell priming Front-loading maximizes cytotoxic response before viral replication peaks. Supported by hepatitis B and influenza
This comparison does not assign a generated winner or score.
- Acute Viral Defense
- 6.4mg initial, then 3.2mg maintenance
- Day 1, then 2× weekly
- 4–8 weeks
- Rapid dendritic cell maturation and CD8+ T-cell priming
- Front-loading maximizes cytotoxic response before viral replication peaks. Supported by hepatitis B and influenza research models
- Bacterial Infection Support
- 3.2mg steady-state
- 2× weekly
- 4–6 weeks or until resolution
- Sustained IL-2/IL-12 production supporting phagocytic activity
- Steady dosing prevents neutrophil exhaustion. Sepsis trials show 28-day mortality reduction with this protocol
- Chronic Immune Restoration
- 1.6mg maintenance
- 2–3× weekly
- 12–24 weeks
- Gradual CD4+ expansion and thymic output restoration
- Lower doses avoid overstimulation in already dysregulated systems. HIV and chemotherapy-induced immunosuppression models use this range
- Pre-Exposure Immune Priming
- 3.2mg single dose
- 48–72 hours pre-exposure
- Single administration or short course
- TLR2-mediated pattern recognition receptor upregulation
- Vaccination studies show 1.8× higher antibody response when dosed 48 hours before antigen exposure
- Post-Surgical Infection Prevention
- 1.6–3.2mg
- 3× weekly
- 2–4 weeks peri-operative
- NK cell activity and wound-site immune surveillance
- Cardiac surgery trials showed 40% reduction in post-op infection rates at 1.6mg 3× weekly starting 1 week pre-surgery